medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2016, Number 619

<< Back Next >>

Rev Med Cos Cen 2016; 73 (619)

Anticoagulación en fibrilación auricular

López MRE

Language: Spanish
References: 15
Page: 273-277
PDF size: 212.02 Kb.


ABSTRACT

We always need to put in perspective the risk and benefit of anticoagulating a patient with atrial fibrillation for preventing thromboembolism and major bleeding as well. This review outlines a rationale for clinical judgement to choose the best therapy.


REFERENCES

  1. Abbott RD, et al; Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306:1018–1022.

  2. BM Jones, Wang TJ, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042– 1046

  3. Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000; 140:886–890.

  4. Cabbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983–988

  5. Casinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35:183–187.

  6. Connolly SJ, GoldMR, etal; ASSERT Investigators.Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366:120–129.

  7. Dalpert JS,etal. 2014 AHA/ACC/ HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071–2104.

  8. Dane CA, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263–272.

  9. Feinberg WM, Hart RG. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators. Neurology 20033; 43:32–36.

  10. Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 20044; 154:1449–1457.

  11. Fusuf S, etal; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–1151.

  12. Garg J, etal; ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883–891.

  13. Granger CB, McMurray JJ, etal; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981–992.

  14. Glund, Stephan, Ph.D; Idarucizuman for dabigatran reversal. N Engl J Med 2015;373;6

  15. Kaatz, Scott; Kong, David; et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015; 373;9




2020     |     www.medigraphic.com